Teva touts positive Phase III for nasal aerosol allergy drug; BDSI wins soluble film cancer drug patent fight

> Teva Pharmaceutical ($TEVA) is touting positive results from four Phase III studies of its QNASLTM dry nasal aerosol corticosteroid to treat seasonal allergies. Release

> CRO Particle Sciences has acquired exclusive rights to Lyotropic Therapeutics' LyoCell patent portfolio. The technology is designed to improve solubility and stability for a wide range of potential drugs, and also increase how effectively they're delivered. Release

> Pono acquired three drug technologies developed by the University of Hawaii, including a nanocarrier drug delivery system, Pacific Business News reports. Story

> The use of microneedle skin patches is more effective at delivering a flu vaccine in mice than injections under the skin or through muscles, according to a new study. Release

> The U.S. Patent Office has again rejected all claims filed by MonoSol against BioDelivery Sciences International ($BDSI) regarding Onsolis, a soluble film cancer pain drug, after reexamining three patents. Release

And Finally… Scientists are developing a number of innovative drug delivery vehicles for sustained-release glaucoma treatments, but obstacles remain before such tech will be widely used, a speaker at the American Glaucoma Society annual meeting said. Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.